Tularik Inc
Article Abstract:
Trials for Tularik Inc.'s drug candidate has started but the company's cash need is precarious. Shares are very risky, ranked to underperform the market for the next 6 - 12 months and investors are advised to look elsewhere.
author: Chow, Nancy
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Biological products industry, Tularik Inc.
Incyte Corp
Article Abstract:
Incyte Corp.'s earnings are expected to drop 40% and losses to increase for the next few years. Shares are only suitable for most risk-tolerant investors.
author: Chow, Nancy
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Health care information services, Medical advice systems, Incyte Corp.
Davita Inc
Article Abstract:
DaVita Inc. expects to have its earnings advance in 2003 and 2004. Shares are timely with above average appreciation potential out to 2006-2008.
author: Chow, Nancy
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
Health care industry, DaVita Inc.
subjects list: United States, Finance, Company investment, Investments, Statistics, Securities, Company sales and earnings, Company earnings/profit, Company securities, Company business forecast/projection, Company forecasts
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.